Ideaya Biosciences (IDYA) announced that Daniel Simon will join the company as its chief business officer in August. Simon most recently served as chief business officer at Revolution Medicines (RVMD) from 2022 to 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences price target lowered to $55 from $57 at JPMorgan
- Ideaya Biosciences reports Q1 EPS (53c), consensus (51c)
- IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
- Ideaya Biosciences announces selection of move-forward expansion dose for IDE397
- Ideaya Biosciences announces inducement grants under Nasdaq listing rule